[시장보고서]세계의 갑상선암 진단 시장 : 시장 규모, 점유율 및 동향 분석(암 유형별·기술별·최종 용도별, 지역별), 부문별 예측(2025-2033년)

세계의 갑상선암 진단 시장 : 시장 규모, 점유율 및 동향 분석(암 유형별·기술별·최종 용도별, 지역별), 부문별 예측(2025-2033년)

Thyroid Cancer Diagnostics Market Size, Share & Trends Analysis Report By Cancer Type (Papillary Carcinoma, Follicular Carcinoma), By Technique (Imaging, Biopsy), By End Use, By Region, And Segment Forecasts, 2025 - 2033

상품코드 : 1842339

리서치사 : Grand View Research

발행일 : 2025년 09월

페이지 정보 : 영문 100 Pages

라이선스 & 가격 (부가세 별도)

US $ 5,950

￦ 8,830,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950

￦ 10,315,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950

￦ 13,283,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

갑상선암 진단 : 시장 개요

세계의 갑상선암 진단 시장 규모는 2024년에 30억 7,000만 달러로 평가되었고, 2033년에는 50억 3,000만 달러에 이르고, 2025년부터 2033년까지 연평균 복합 성장률(CAGR)은 5.86%를 보일 전망입니다.

이러한 성장은 갑상선암 발병률 증가, 조기 검진 프로그램에 대한 인식 증가, 영상 진단법 및 분자 검사 등 진단 도구의 기술 발전으로 인한 것입니다.

또한, 의료비 지출 증가, 유리한 상환 정책, 개인 맞춤형 의료로의 전환을 들 수 있습니다. 또한, 고령화 인구 증가, 의료 인프라의 개선, 지속적인 연구개발 노력은 갑상선암의 조기 발견과 관리를 가능하게 하는 시장 확대를 더욱 촉진하고 있습니다.

갑상선암 진단에는 영상진단, 생검, 혈액검사, 분자프로파일링 등 갑상선암을 발견하고 특징짓는 데 사용되는 다양한 검사 및 시술이 포함되며, 임상적 판단과 맞춤 치료를 위한 지침이 됩니다. 이러한 진단약 세계 시장은 빠르게 성장하고 있으며, 그 주요 원인은 갑상선암 환자 증가에 기인합니다. 이러한 환자 수 증가로 인해 조기 발견과 효과적인 스크리닝 도구에 대한 수요가 증가하고 있으며, 의료 서비스 제공업체들은 예후를 개선하기 위해 적극적인 식별을 우선시하고 있습니다. 미국암협회에 따르면, 2025년에는 미국에서 약 44,020건의 갑상선암이 새롭게 진단될 것으로 예측됩니다. 약 31,350건이 여성에게, 약 12,670건이 남성에게 발생합니다. 갑상선암은 여성에게 많이 발생하며, 다른 암에 비해 젊은 나이에 진단되는 경우가 많습니다.

이 시장의 큰 원동력은 기술의 발전입니다. 예를 들어, GE헬스케어는 2024년 5월 첨단 방사선 치료용 컴퓨터 단층촬영(CT) 솔루션인 Revolution RT를 발표했습니다. 이 혁신적인 시스템은 이미지의 정확도를 높이고, 시뮬레이션 워크플로우를 간소화하며, 보다 개인화되고 원활한 종양 치료를 지원하도록 설계되었습니다. Revolution RT는 AI 기반 기술과 최신 소프트웨어 플랫폼을 통합하여 임상의가 정확한 종양 표적화와 보다 효율적인 치료 경로를 구현할 수 있도록 지원합니다.

또한, 원격 의료와 디지털 헬스 플랫폼의 도입으로 갑상선암 진단에 대한 접근성이 더욱 확대되고 있으며, 특히 원격지나 의료서비스가 부족한 지역의 사람들에게는 더욱 큰 도움이 되고 있습니다. 가상 진찰을 통해 환자는 조기 검진 추천 및 후속 치료를 받을 수 있으며, 지리적 장벽에 관계없이 적시에 개입할 수 있습니다.

또한, 유전적 위험인자에 대한 유전자 검사가 대중화되고 있는 것도 시장에 새로운 기회를 창출하고 있습니다. 첨단 유전체 패널은 갑상선 종양과 관련된 돌연변이를 식별할 수 있어 보다 정확한 진단과 맞춤형 치료 전략을 수립하는 데 도움을 줄 수 있습니다. 갑상선암 발병률 증가, Revolution RT와 같은 최첨단 기술, 개인 맞춤형 의료로의 전환, 디지털 헬스 접근성, 유전자 검사 확대 등 이러한 요인들이 종합적으로 갑상선암 진단 산업의 강력한 성장을 가속하고 조기 발견과 환자 치료의 개선으로 이어질 것입니다.

시장 대시보드 : 지역별
시장 점유율 분석 : 지역별(2024년·2033년)
갑상선암 진단 시장 : 주요 포인트, 지역별
북미
- 미국
- 캐나다
- 멕시코
유럽
- 독일
- 영국
- 프랑스
- 이탈리아
- 스페인
- 덴마크
- 스웨덴
- 노르웨이
아시아태평양
- 일본
- 중국
- 인도
- 호주
- 태국
- 한국
라틴아메리카
- 브라질
- 아르헨티나
중동 및 아프리카
- 남아프리카공화국
- 사우디아라비아
- 아랍에미리트(UAE)
- 쿠웨이트

제8장 경쟁 구도

주요 시장 진출기업의 최근 동향과 영향 분석
기업/경쟁 분류
벤더 구도
- 주요 기업 히트맵 분석(2024년)
기업 개요
- Abbott
- F.Hoffmann-La Roche Ltd.
- Thermo Fisher Scientific, Inc.
- Siemens Healthcare GmbH
- Bio-Rad Laboratories, Inc.
- GE HealthCare
- Hologic, Inc.
- Koninklijke Philips NV
- Toshiba Corporation
- Agilent Technologies, Inc.
- Illumina, Inc.

LSH

영문 목차

영문목차

Thyroid Cancer Diagnostics Market Summary

The global thyroid cancer diagnostics market size was estimated at USD 3.07 billion in 2024 and is projected to reach USD 5.03 billion by 2033, growing at a CAGR of 5.86% from 2025 to 2033. This growth is attributed to the growing incidence of thyroid cancer, growing awareness of early screening programs, and significant technological advancements in diagnostic tools such as imaging modalities and molecular testing.

In addition, increased healthcare spending, favorable reimbursement policies, and a shift toward personalized medicine. Furthermore, the growing aging population, improved healthcare infrastructure, and ongoing research and development efforts further support market expansion, enabling earlier and more accurate detection and management of thyroid cancer.

Thyroid cancer diagnostics encompass a broad range of tests and procedures, including imaging, biopsies, blood tests, and molecular profiling used to detect and characterize thyroid cancer, guiding clinical decisions and personalized treatment. The global market for these diagnostics is expanding rapidly, largely due to the increasing number of thyroid cancer patients. This rise in cases has heightened the demand for early detection and effective screening tools, as healthcare providers prioritize proactive identification to improve outcomes. According to the American Cancer Society, about 44,020 new cases of thyroid cancer are expected to be diagnosed in the U.S. in 2025. Approximately 31,350 cases occur in women and 12,670 in men. Thyroid cancer is notably more common in women and is often diagnosed at a younger age compared to many other cancers.

A significant driver of this market is technological advancement. For instance, in May 2024, GE Healthcare introduced Revolution RT, an advanced radiation therapy computed tomography (CT) solution. This innovative system is designed to enhance imaging accuracy and streamline simulation workflows, supporting a more personalized and seamless oncology care experience. Revolution RT incorporates AI-driven technologies and updated software platforms, enabling clinicians to achieve precise tumor targeting and more efficient care pathways.

In addition, the adoption of telemedicine and digital health platforms has further expanded access to thyroid cancer diagnostics, especially for individuals in remote or underserved areas. Through virtual consultations, patients can receive early screening recommendations and follow-up care, ensuring timely intervention regardless of geographic barriers.

Moreover, the growing prevalence of genetic testing for hereditary risk factors is creating new opportunities in the market. Advanced genomic panels can identify mutations linked to thyroid tumors, aiding in more accurate diagnosis and personalized treatment strategies. Collectively, these factors, including the rising incidence of thyroid cancer, cutting-edge technology like Revolution RT, the shift toward personalized medicine, digital health accessibility, and expanded genetic testing, are driving robust growth in the thyroid cancer diagnostics industry, leading to earlier detection and improved patient care.

Global Thyroid Cancer Diagnostics Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global thyroid cancer diagnostics market report based on cancer type, technique, end use, and region.

Cancer Type Outlook (Revenue, USD Million, 2021 - 2033)
Papillary carcinoma
Follicular carcinoma
Others
Technique Outlook (Revenue, USD Million, 2021 - 2033)
Blood Test
Imaging
Biopsy
Others
End Use Indication Outlook (Revenue, USD Million, 2021 - 2033)
Hospital Laboratories
Cancer Diagnostic Centers
Research Institutes
Others
Regional Outlook (Revenue, USD Million, 2021 - 2033)
North America
- U.S.
- Canada
- Mexico
Europe
- UK
- Germany
- Spain
- France
- Italy
- Denmark
- Norway
- Sweden
Asia Pacific
- Japan
- China
- India
- South Korea
- Australia
- Thailand
Latin America
- Brazil
- Argentina
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Segment Definitions
- 1.2.1. Cancer Type
- 1.2.2. Technique
- 1.2.3. End Use
1.3. Research Methodology
1.4. Information Procurement
- 1.4.1. Purchased Database
- 1.4.2. GVR's Internal Database
- 1.4.3. Secondary Sources
- 1.4.4. Primary Research
1.5. Information or Data Analysis
- 1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.8. List of Secondary Sources
1.9. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
- 2.2.1. Cancer Type Outlook
- 2.2.2. Technique Outlook
- 2.2.3. End Use Outlook
- 2.2.4. Regional Outlook
2.3. Competitive Insights

Chapter 3. Global Thyroid Cancer Diagnostics Market Variables, Trends, & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
3.3. Global Thyroid Cancer Diagnostics Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
  - 3.3.1.1. Supplier Power
  - 3.3.1.2. Buyer Power
  - 3.3.1.3. Substitution Threat
  - 3.3.1.4. Threat of New Entrants
  - 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis
  - 3.3.2.1. Political Landscape
  - 3.3.2.2. Technological Landscape
  - 3.3.2.3. Economic Landscape

Chapter 4. Global Thyroid Cancer Diagnostics Market: Cancer Type Business Analysis

4.1. Cancer Type Segment Dashboard
4.2. Thyroid Cancer Diagnostics Market: Cancer Type Movement Analysis
4.3. Global Thyroid Cancer Diagnostics Market Size & Trend Analysis, By Cancer Type, 2021 to 2033 (USD Million)
4.4. Papillary carcinoma
- 4.4.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
4.5. Follicular carcinoma
- 4.5.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
4.6. Others
- 4.6.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)

Chapter 5. Global Thyroid Cancer Diagnostics Market: Technique Business Analysis

5.1. Technique Segment Dashboard
5.2. Thyroid Cancer Diagnostics Market: Technique Movement Analysis
5.3. Global Thyroid Cancer Diagnostics Market Size & Trend Analysis, By Technique, 2021 to 2033 (USD Million)
5.4. Blood Test
- 5.4.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
5.5. Imaging
- 5.5.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
5.6. Biopsy
- 5.6.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
5.7. Others
- 5.7.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)

Chapter 6. Global Thyroid Cancer Diagnostics Market: End Use Business Analysis

6.1. End Use Segment Dashboard
6.2. Thyroid Cancer Diagnostics Market: End Use Movement Analysis
6.3. Global Thyroid Cancer Diagnostics Market Size & Trend Analysis, By End Use, 2021 to 2033 (USD Million)
6.4. Hospital Laboratories
- 6.4.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
6.5. Cancer Diagnostic Centers
- 6.5.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
6.6. Research Institutes
- 6.6.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
6.7. Others
- 6.7.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)

Chapter 7. Global Thyroid Cancer Diagnostics Market: Regional Estimates & Trend Analysis

7.1. Regional Market Dashboard
7.2. Regional Market Share Analysis, 2024 & 2033
7.3. Global Thyroid Cancer Diagnostics Market by Regional: Key Takeaways
7.4. North America
- 7.4.1. U.S.
  - 7.4.1.1. Key Country Dynamics
  - 7.4.1.2. Regulatory Framework/ Reimbursement Structure
  - 7.4.1.3. Competitive Scenario
  - 7.4.1.4. U.S. Market Estimates and Forecasts 2021 to 2033 (USD Million)
- 7.4.2. Canada
  - 7.4.2.1. Key Country Dynamics
  - 7.4.2.2. Regulatory Framework/ Reimbursement Structure
  - 7.4.2.3. Competitive Scenario
  - 7.4.2.4. Canada Market Estimates and Forecasts 2021 to 2033 (USD Million)
- 7.4.3. Mexico
  - 7.4.3.1. Key Country Dynamics
  - 7.4.3.2. Regulatory Framework/ Reimbursement Structure
  - 7.4.3.3. Competitive Scenario
  - 7.4.3.4. Mexico Market Estimates and Forecasts 2021 to 2033 (USD Million)
7.5. Europe
- 7.5.1. Germany
  - 7.5.1.1. Key Country Dynamics
  - 7.5.1.2. Regulatory Framework/ Reimbursement Structure
  - 7.5.1.3. Competitive Scenario
  - 7.5.1.4. Germany Market Estimates and Forecasts 2021 to 2033 (USD Million)
- 7.5.2. UK
  - 7.5.2.1. Key Country Dynamics
  - 7.5.2.2. Regulatory Framework/ Reimbursement Structure
  - 7.5.2.3. Competitive Scenario
  - 7.5.2.4. UK Market Estimates and Forecasts 2021 to 2033 (USD Million)
- 7.5.3. France
  - 7.5.3.1. Key Country Dynamics
  - 7.5.3.2. Regulatory Framework/ Reimbursement Structure
  - 7.5.3.3. Competitive Scenario
  - 7.5.3.4. France Market Estimates and Forecasts 2021 to 2033 (USD Million)
- 7.5.4. Italy
  - 7.5.4.1. Key Country Dynamics
  - 7.5.4.2. Regulatory Framework/ Reimbursement Structure
  - 7.5.4.3. Competitive Scenario
  - 7.5.4.4. Italy Market Estimates and Forecasts 2021 to 2033 (USD Million)
- 7.5.5. Spain
  - 7.5.5.1. Key Country Dynamics
  - 7.5.5.2. Regulatory Framework/ Reimbursement Structure
  - 7.5.5.3. Competitive Scenario
  - 7.5.5.4. Spain Market Estimates and Forecasts 2021 to 2033 (USD Million)
- 7.5.6. Denmark
  - 7.5.6.1. Key Country Dynamics
  - 7.5.6.2. Regulatory Framework/ Reimbursement Structure
  - 7.5.6.3. Competitive Scenario
  - 7.5.6.4. Denmark Market Estimates and Forecasts 2021 to 2033 (USD Million)
- 7.5.7. Sweden
  - 7.5.7.1. Key Country Dynamics
  - 7.5.7.2. Regulatory Framework/ Reimbursement Structure
  - 7.5.7.3. Competitive Scenario
  - 7.5.7.4. Sweden Market Estimates and Forecasts 2021 to 2033 (USD Million)
- 7.5.8. Norway
  - 7.5.8.1. Key Country Dynamics
  - 7.5.8.2. Regulatory Framework/ Reimbursement Structure
  - 7.5.8.3. Competitive Scenario
  - 7.5.8.4. Norway Market Estimates and Forecasts 2021 to 2033 (USD Million)
7.6. Asia Pacific
- 7.6.1. Japan
  - 7.6.1.1. Key Country Dynamics
  - 7.6.1.2. Regulatory Framework/ Reimbursement Structure
  - 7.6.1.3. Competitive Scenario
  - 7.6.1.4. Japan Market Estimates and Forecasts 2021 to 2033 (USD Million)
- 7.6.2. China
  - 7.6.2.1. Key Country Dynamics
  - 7.6.2.2. Regulatory Framework/ Reimbursement Structure
  - 7.6.2.3. Competitive Scenario
  - 7.6.2.4. China Market Estimates and Forecasts 2021 to 2033 (USD Million)
- 7.6.3. India
  - 7.6.3.1. Key Country Dynamics
  - 7.6.3.2. Regulatory Framework/ Reimbursement Structure
  - 7.6.3.3. Competitive Scenario
  - 7.6.3.4. India Market Estimates and Forecasts 2021 to 2033 (USD Million)
- 7.6.4. Australia
  - 7.6.4.1. Key Country Dynamics
  - 7.6.4.2. Regulatory Framework/ Reimbursement Structure
  - 7.6.4.3. Competitive Scenario
  - 7.6.4.4. Australia Market Estimates and Forecasts 2021 to 2033 (USD Million)
- 7.6.5. Thailand
  - 7.6.5.1. Key Country Dynamics
  - 7.6.5.2. Regulatory Framework/ Reimbursement Structure
  - 7.6.5.3. Competitive Scenario
  - 7.6.5.4. Thailand Market Estimates and Forecasts 2021 to 2033 (USD Million)
- 7.6.6. South Korea
  - 7.6.6.1. Key Country Dynamics
  - 7.6.6.2. Regulatory Framework/ Reimbursement Structure
  - 7.6.6.3. Competitive Scenario
  - 7.6.6.4. South Korea Market Estimates and Forecasts 2021 to 2033 (USD Million)
7.7. Latin America
- 7.7.1. Brazil
  - 7.7.1.1. Key Country Dynamics
  - 7.7.1.2. Regulatory Framework/ Reimbursement Structure
  - 7.7.1.3. Competitive Scenario
  - 7.7.1.4. Brazil Market Estimates and Forecasts 2021 to 2033 (USD Million)
- 7.7.2. Argentina
  - 7.7.2.1. Key Country Dynamics
  - 7.7.2.2. Regulatory Framework/ Reimbursement Structure
  - 7.7.2.3. Competitive Scenario
  - 7.7.2.4. Argentina Market Estimates and Forecasts 2021 to 2033 (USD Million)
7.8. Middle East & Africa
- 7.8.1. South Africa
  - 7.8.1.1. Key Country Dynamics
  - 7.8.1.2. Regulatory Framework/ Reimbursement Structure
  - 7.8.1.3. Competitive Scenario
  - 7.8.1.4. South Africa Market Estimates and Forecasts 2021 to 2033 (USD Million)
- 7.8.2. Saudi Arabia
  - 7.8.2.1. Key Country Dynamics
  - 7.8.2.2. Regulatory Framework/ Reimbursement Structure
  - 7.8.2.3. Competitive Scenario
  - 7.8.2.4. South Arabia Market Estimates and Forecasts 2021 to 2033 (USD Million)
- 7.8.3. UAE
  - 7.8.3.1. Key Country Dynamics
  - 7.8.3.2. Regulatory Framework/ Reimbursement Structure
  - 7.8.3.3. Competitive Scenario
  - 7.8.3.4. UAE Market Estimates and Forecasts 2021 to 2033 (USD Million)
- 7.8.4. Kuwait
  - 7.8.4.1. Key Country Dynamics
  - 7.8.4.2. Regulatory Framework/ Reimbursement Structure
  - 7.8.4.3. Competitive Scenario
  - 7.8.4.4. Kuwait Market Estimates and Forecasts 2021 to 2033 (USD Million)

Chapter 8. Competitive Landscape

8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.3. Vendor Landscape
- 8.3.1. Key Company Heat Map Analysis, 2024
8.4. Company Profiles
- 8.4.1. Abbott
  - 8.4.1.1. Company Overview
  - 8.4.1.2. Financial Performance
  - 8.4.1.3. Product Benchmarking
  - 8.4.1.4. Strategic Initiatives
- 8.4.2. F.Hoffmann-La Roche Ltd.
  - 8.4.2.1. Company Overview
  - 8.4.2.2. Financial Performance
  - 8.4.2.3. Product Benchmarking
  - 8.4.2.4. Strategic Initiatives
- 8.4.3. Thermo Fisher Scientific, Inc.
  - 8.4.3.1. Company Overview
  - 8.4.3.2. Financial Performance
  - 8.4.3.3. Product Benchmarking
  - 8.4.3.4. Strategic Initiatives
- 8.4.4. Siemens Healthcare GmbH
  - 8.4.4.1. Company Overview
  - 8.4.4.2. Financial Performance
  - 8.4.4.3. Product Benchmarking
  - 8.4.4.4. Strategic Initiatives
- 8.4.5. Bio-Rad Laboratories, Inc.
  - 8.4.5.1. Company Overview
  - 8.4.5.2. Financial Performance
  - 8.4.5.3. Product Benchmarking
  - 8.4.5.4. Strategic Initiatives
- 8.4.6. GE HealthCare
  - 8.4.6.1. Company Overview
  - 8.4.6.2. Financial Performance
  - 8.4.6.3. Product Benchmarking
  - 8.4.6.4. Strategic Initiatives
- 8.4.7. Hologic, Inc.
  - 8.4.7.1. Company Overview
  - 8.4.7.2. Financial Performance
  - 8.4.7.3. Product Benchmarking
  - 8.4.7.4. Strategic Initiatives
- 8.4.8. Koninklijke Philips N.V.
  - 8.4.8.1. Company Overview
  - 8.4.8.2. Financial Performance
  - 8.4.8.3. Product Benchmarking
  - 8.4.8.4. Strategic Initiatives
- 8.4.9. Toshiba Corporation
  - 8.4.9.1. Company Overview
  - 8.4.9.2. Financial Performance
  - 8.4.9.3. Product Benchmarking
  - 8.4.9.4. Strategic Initiatives
- 8.4.10. Agilent Technologies, Inc.
  - 8.4.10.1. Company Overview
  - 8.4.10.2. Financial Performance
  - 8.4.10.3. Product Benchmarking
  - 8.4.10.4. Strategic Initiatives
- 8.4.11. Illumina, Inc.
  - 8.4.11.1. Company Overview
  - 8.4.11.2. Financial Performance
  - 8.4.11.3. Product Benchmarking
  - 8.4.11.4. Strategic Initiatives

한글목차

갑상선암 진단 : 시장 개요

목차

제1장 분석 방법과 범위

제2장 주요 요약

제3장 세계의 갑상선암 진단 시장 : 변동 요인, 동향 및 범위

제4장 세계의 갑상선암 진단 시장 : 암 유형별 비즈니스 분석

제5장 세계의 갑상선암 진단 시장 : 기술별 비즈니스 분석

제6장 세계의 갑상선암 진단 시장 : 최종 용도별 비즈니스 분석

제7장 세계의 갑상선암 진단 시장 : 지역별 추정·동향 분석